What is the appropriate initial management and treatment plan for a patient presenting with an upper gastrointestinal bleed?

Initial Management of Upper Gastrointestinal Bleeding

For a patient presenting with upper GI bleeding, immediately initiate resuscitation with a restrictive transfusion threshold of 7 g/dL, start IV PPI therapy, administer erythromycin 30-60 minutes before endoscopy, and perform endoscopy within 24 hours of presentation. 1, 2

Immediate Resuscitation and Risk Stratification

Fluid resuscitation and blood product management:

• Transfuse red blood cells only when hemoglobin drops below 7 g/dL (unless the patient has cardiovascular disease, where a higher threshold may be appropriate) 1, 2
• This restrictive strategy improves mortality and morbidity outcomes
• Establish large-bore IV access and begin crystalloid resuscitation as needed

Risk stratification in the emergency department:

• Use the Glasgow-Blatchford score to identify very low-risk patients (score 0-1) who can be safely discharged with outpatient follow-up 2
• Higher-risk patients require hospital admission and urgent endoscopy

Pre-Endoscopic Pharmacologic Management

Proton pump inhibitor (PPI) therapy:

• Start IV PPI immediately upon presentation 1
• Pre-endoscopic PPI therapy downstages endoscopic lesions and decreases the need for endoscopic intervention, though it should not delay endoscopy 1
• Do NOT use H2-receptor antagonists (HRAs) - they are not recommended for acute ulcer bleeding 1

Erythromycin administration:

• Give erythromycin infusion 30-60 minutes before endoscopy to improve visualization 2
• This prokinetic agent clears the stomach of blood and clots, increasing diagnostic yield

Important caveat: Somatostatin and octreotide are NOT routinely recommended for nonvariceal upper GI bleeding 1. Reserve these for suspected variceal bleeding in patients with known cirrhosis.

Timing of Endoscopy

Perform endoscopy within 24 hours of presentation after initial stabilization 1, 2

• This is a conditional recommendation with very low-quality evidence, but represents international consensus
• Do not delay endoscopy in patients receiving anticoagulants (vitamin K antagonists or DOACs) 1
• Earlier endoscopy (within 12 hours) may be considered for high-risk patients, though routine very early endoscopy has not shown mortality benefit

Endoscopic Hemostatic Therapy

For high-risk stigmata (active spurting/oozing or visible vessel):

• Strongly recommend endoscopic hemostatic therapy with thermocoagulation or sclerosant injection 1
• Through-the-scope clips are also suggested as an option 1
• Never use epinephrine injection alone - it provides suboptimal efficacy and must be combined with another method 1
• No single thermal coaptive method is superior to another 1

For low-risk stigmata:

• Clean-based ulcers or flat pigmented spots do NOT require endoscopic therapy 1
• For adherent clots: attempt targeted irrigation to dislodge; if a high-risk lesion is revealed underneath, treat it. If the clot remains adherent, endoscopic therapy may be considered though intensive PPI alone may suffice 1

Newer modalities:

• TC-325 hemostatic powder spray can be used as temporizing therapy when conventional methods are unavailable or fail, but should NOT be used as a single therapeutic strategy 1, 2
• Over-the-scope clips (OTSCs) are suggested for recurrent ulcer bleeding after previous successful hemostasis 2

Post-Endoscopic Management

PPI therapy after successful endoscopic hemostasis:

• Administer IV PPI as a loading dose followed by continuous infusion for 72 hours (strong recommendation, moderate-quality evidence) 1
• After 3 days of high-dose IV PPI, transition to twice-daily oral PPI for 14 days, then once daily 1
• This regimen significantly reduces rebleeding risk

Hospital monitoring:

• Patients who undergo endoscopic hemostasis for high-risk stigmata should be hospitalized for at least 72 hours 1
• Low-risk patients after endoscopy can be fed within 24 hours and may be discharged promptly 1

Management of Rebleeding

If rebleeding occurs:

• A second attempt at endoscopic therapy is generally recommended 1
• Routine second-look endoscopy is NOT recommended in stable patients 1
• If endoscopic therapy fails after repeat attempt, seek surgical consultation 1
• Where available, percutaneous transcatheter embolization is suggested as an alternative to surgery 1, 2

Critical Post-Discharge Considerations

Helicobacter pylori testing and eradication:

• All patients with bleeding peptic ulcers must be tested for H. pylori and receive eradication therapy if positive, with confirmation of eradication 1
• Negative H. pylori tests obtained during acute bleeding should be repeated, as acute bleeding can cause false negatives 1

Antiplatelet and anticoagulation management:

• For patients on low-dose aspirin who develop ulcer bleeding, restart aspirin as soon as cardiovascular risk outweighs bleeding risk 1
• For patients requiring continued antiplatelet or anticoagulation therapy, add PPI therapy to reduce recurrent bleeding risk 1
• Discharge all patients on once-daily oral PPI for duration dictated by underlying cause 1

Common pitfall: Do not routinely use promotility agents before endoscopy to increase diagnostic yield - erythromycin is the exception with specific evidence 1. Avoid tranexamic acid in upper GI bleeding 3.